company logo
Board of Directors



Ken Powell PhD Chairman

Chairman of ReViral;

Former roles Executive Chairman Q-Chip a Cardiff, Wales based life science company developing novel delayed release formulations of drugs. In 2014 Q-Chip merged with Midatech which then listed on the LSE (AIM) market.

Founder and CEO of Arrow Therapeutics Ltd (a specialised antiviral drug discovery company acquired by Astra-Zeneca PLC for $150 million in February 2007).

Ken has more than 30 years experience of the pharmaceutical industry and the biotechnology sector. He is an expert virologist and has been involved in the development of multiple anti-viral compounds.

Eddy Littler Chief Executive Officer

Eddy began his research career at the University of Leeds studying herpesvirus DNA replication. After postdoctoral research at McMaster University in Canada, he joined the Paterson Institute for Cancer Research in Manchester. Here Eddy investigated viruses and cancer including Epstein-Barr virus and Human Herpesvirus type 6. After six successful years, he joined the Wellcome Research Laboratories as Head of Herpes Virus Research. During his time at Wellcome, he became Head of the Gene Targets Group which had projects in herpesviruses, respiratory viruses, including RSV, and gene therapy of ovarian cancer. Following the acquisition of Wellcome by Glaxo he became Head of Antiviral Research at GlaxoWellcome leading teams working on hepatitis C virus, influenza virus, and respiratory syncytial virus.  

Eddy left GSK in 2000 to join Medivir as Senior Director of Lead Discovery and Head of UK Operations. While at Medivir he played a significant role in several deals, including the development and eventual out-licensing of the HCV protease inhibitor (Simeprevir) programme to Tibotec (J&J). The total value of transactions converted at Medivir was $360M.

Eddy became the Chief Executive Officer of Domainex in May 2008. He developed Domainex to become one of the UKs leading drug discovery CROs. Under his leadership, Domainex also developed a pipeline of drugs aimed at inflammation and cancer. Eddy consults for a number of companies and NGOs.


Stuart Cockerill PhD Chief Scientific Officer, Founder
Stuart is the Principal Investigator on the Wellcome Trust funded Project, on behalf of ReVIRAL. He obtained his Ph.D. in Organic Chemistry at the University of Leeds. After Postdoctoral fellowship at Cornell University he joined the GSK heritage company, the Wellcome Foundation and over the next 15 years led drug discovery projects in Pesticides, Immunology, Virology and Oncology. His key achievement was leading the erbB2 Oncology Project Team that discovered Tykerb™ for which Stuart is a named inventor. In December 2000, Stuart joined Arrow Therapeutics as Head of Chemistry and subsequently as Research Director. Key achievements were two clinical Proof of Concept drug candidates involving novel approaches to the treatment of Respiratory Syncytial Virus and Hepatitis C Virus infection. Stuart remained as Head of Arrow until the end of 2010. Stuart is an author of over 70 papers, patents and book chapters and is Senior Lecturer in Medicinal Chemistry at the University of Durham.
Dr. Raymond F. Schinazi Non-Executive Director

Dr. Raymond F Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University. He serves as Senior Research Career Scientist at the Atlanta Department of Veterans Affairs and Director of the Scientific Working Group on Viral Eradication for the NIH-sponsored Emory University Center for AIDS Research (CFAR).  Dr. Schinazi received his BSc (1972) and PhD (1976) in chemistry from the University of Bath, England.  A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV, HBV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine/Emtriva), LdT (telbivudine), and most recently sofosbuvir (Sovaldi), which are now approved by the FDA. More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented, and it is estimated that his work has saved more than 6.5 million lives worldwide. His contributions related to HCV are expected to have a profound positive impact on the approximately 170 million people worldwide suffering from chronic infection.

Dr. Schinazi has been the recipient of numerous awards chronicling his track record of innovation and contributions to medical science including an honorary degree from Bath University, his Alma mater, the 2000 Bruce Witte Annual Distinguished Award from the Hepatitis B foundation, the Research and Hope Award for Excellence in Academic Research from the Pharmaceutical Research and Manufacturers of America (PhRMA) organization and the Distinguished Scientific Achievement Award from the American Liver Foundation. He served on the Presidential commission for AIDS during the Clinton administration.

Raphaël Wisniewski Partner, Edmond de Rothschild Investment Partners

Raphaël began his career in London, where he spent seven years in the healthcare and investment banking industries. He was first part of the finance department of Générale de Santé International in London, the largest private hospitals group in the UK, where he held treasury and investment analysis functions. He subsequently worked in the healthcare groups of the Investment Banking divisions of Salomon Smith Barney (1996-1999) and Goldman Sachs (1999-2001) where he participated in many M&A and capital raising deals within pharmaceuticals, medical devices, biotechnology and services companies. Since joining EdRIP in 2001 he has worked on several investments, IPOs and trade sales in the biotechnology and medical device sectors. He currently sits on the boards of Cellnovo Group, Poxel, Genticel, Implanet, Chase Pharmaceuticals and Axonics.

Raphaël graduated from the French business school HEC in 1993 and received a Masters in Applied Economics from Institut d'Etudes Politiques in 1994.
Chau Q. Khuong Private Equity Partner, OrbiMed

Chau joined OrbiMed Advisors in 2003 and is a Private Equity Partner focused on structured investments in private and public biopharmaceutical and medical device companies.  Mr. Khuong has been extensively involved with development and commercial stage companies in multiple therapeutic areas from cancer to anti-infectives to liver diseases and ophthalmology.  He is currently a Board Director or Observer at Aerpio, Cerapedics, Glaukos (NYSE: GKOS), Intercept Pharmaceuticals (NASDAQ: ICPT), Inspire Medical Systems, Intellia Therapeutics, Nabriva Pharmaceuticals, Otonomy (NASDAQ: OTIC), Pieris (NASDAQ: PIRS), Rempex, and Sonendo.  

Prior to OrbiMed, Mr. Khuong worked in start-up operations and business development at Veritas Medicine and also has experience in basic science research at Yale School of Medicine and Massachusetts General Hospital. Mr. Khuong holds a BS (Molecular Biology) and an MPH (Infectious Diseases) from Yale University.

Timothy Jinks PhD Wellcome Trust Innovations Team

Tim is a member of the Wellcome Trust Innovations team with the primary goal of translating novel research into health products and public health tools in areas of unmet medical need.  Tim currently has a portfolio of over a dozen projects and serves as Wellcome Trust board observer at Sentinel Oncology.  Prior to joining the Trust in 2012 he has over a decade of industry experience, most recently as a consultant providing business development, licensing and commercial research services.  Previously he was a Business Development executive at BTG International working on licensing and IP development.  His industry experience started as senior scientist with Iclectus Ltd, a spin-out company from the MRC Laboratory of Molecular Biology, Cambridge that developed an antibody engineering platform.

He trained as a professional chemist at the University of Georgia obtaining the ACS BS in Chemistry before gaining his MA and PhD in Molecular Biology at Princeton University leading to postdoctoral research at the National Institute for Medical Research at Mill Hill, London.

Iain D. Dukes D.Phil Non-Executive Director
Iain D. Dukes, D.Phil., is a Venture Partner with OrbiMed. Iain also serves on the Board of Lion Biotechnologies. Most  recently Iain was a Senior Vice President, Business Development & Licensing Merck where he oversaw all licensing deals for Merck Research Laboratories, including external research, out-licensing, regional deals and academic alliances. Iain has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, as well as consulting for numerous biotech and venture capital organizations. Before joining Merck, he served as vice president of External Research and Development at Amgen. He has also held positions as president and CEO of Essentialis Therapeutics and as Vice President, Scientific and Technology Licensing at GlaxoSmithKline. Iain received his D.Phil. degree from the University of Oxford where he also received a B.A. in Jurisprudence.